Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
CA 2023630 C · Owner: Orion-Yhtyma Oy · Inventors: Kangas, Lauri Veikko Matti; Harris, Adrian Llewellyn; Degregorio, Michael William
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound comprising toremifene or its metabolite N-demethyltoremifene or 4-hydroxytoremifene or a non-toxic, pharmaceutically acceptable salt thereof may be used for the reversal of multidrug resistance of cancer cells to cytotoxic drugs in the treatment of cancer with at least one cytotoxic drug.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 20, 1990 and granted February 19, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 20, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 20, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.